Lumanity As Your BD&L Partner

Introduction

For biopharma leaders, BD&L isn’t about just adding to the pipeline — it’s about making billion-dollar decisions in high-risk, fiercely competitive markets. Analyses of major transactions over the last two decades show that underperformance is often driven by strategic missteps, not just clinical failures.

Studies show up to 34% of drug launches miss sales forecasts, often due to market access and pricing challenges (Deloitte). For assets acquired or licensed through BD&L, these risks can be magnified. Additionally, 27% of deals have been overvalued, while 18% struggled from competitive pressures or misalignment (PwC; Evaluate). Collectively, these issues have erased tens of billions in anticipated deal value,
particularly in crowded therapeutic areas like oncology and neurology.